TV News LIES

Saturday, Aug 30th

Last update06:55:34 PM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


U.S. judge halts major part of Texas law restricting abortions

Texas abortion lawA U.S. judge struck down parts of a law seen as restricting abortions in Texas, saying...

Big Food to divulge chemical info

Big Food to reveal chemicalsFood companies are trying to beat the federal government’s push to make chemicals in food more...

Senegal confirms first case of Ebola

Ebola in SenegalThe first case of Ebola has been confirmed in Senegal, a major hub for West Africa’s...

WHO: Ebola outbreak accelerates, could infect 20,000 people

Ebola outbreakThe Ebola outbreak could infect more than 20,000 people within nine months, and efforts to halt...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!